ClinicalTrials.gg

Program

efanesoctocog alfa

Also written as “Efanesoctocog alfa”, “efanesoctocog alfa (BIVV001)” and “BIVV001 (Low Dose)”.

Its studies are mostly in Hemophilia A · von Willebrand Diseases, led by 2 companies.

Furthest: phase 4, since Apr 16, 202512 company-led studies, 5 open or runningNext primary completion: Nov 17, 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi72 open or runningphase 4since Apr 16, 2025Jun 29, 2017Jan 15, 2027phase 3 · NCT04644575
Swedish Orphan Biovitrum53 open or runningphase 4since Dec 18, 2024Mar 21, 2023Nov 17, 2026phase 4 · NCT06752850

Also a collaborator on its studies: PSI CRO.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 29, 2017First study: phase 2 study in Hemophilia ANew to SanofiSanofi · NCT03205163 · 16 enrolled · United States, Japan
  2. Nov 5, 2019Phase 3 study in Hemophilia ASanofi · NCT04161495 · 159 enrolled · United States, Argentina, Australia and more
  3. Nov 23, 2020Phase 3 study in Hemophilia ASanofi · NCT04644575 · 261 enrolled · United States, Argentina, Australia and more
  4. Feb 13, 2021Phase 3 study in Hemophilia ASanofi · NCT04759131 · 74 enrolled · United States, Australia, Canada and more
  5. Feb 22, 2021Phase 1 study in von Willebrand DiseasesSanofi · NCT04770935 · 6 enrolled · United States, France
  6. Aug 12, 2021Phase 1 study in Hemophilia ASanofi · NCT05042440 · 13 enrolled · Bulgaria
  7. Mar 21, 2023Swedish Orphan Biovitrum’s first study: phase 3 study in Hemophilia ANew to Swedish Orphan BiovitrumSwedish Orphan Biovitrum · NCT05817812 · 93 enrolled · Austria, Croatia, Czechia and more
  8. Aug 28, 2024Phase 1 study in Hemophilia ASwedish Orphan Biovitrum · NCT06579144 · 24 enrolled · Bulgaria, Germany, Italy and more
  9. Oct 2, 2024Phase 3 study in Hemophilia ASwedish Orphan Biovitrum · NCT06716814 · 89 enrolled · Bulgaria, France, Greece and more
  10. Dec 18, 2024Phase 4 study in Hemophilia ASwedish Orphan Biovitrum · NCT06752850 · 37 enrolled · Italy, Norway, Spain and more
  11. Apr 16, 2025Phase 4 study in Hemophilia ASanofi · NCT06941870 · 35 planned · United States, Australia, Canada and more
  12. Apr 16, 2025Phase 4 study in Hemophilia ASwedish Orphan Biovitrum · NCT06940830 · 252 enrolled · Croatia, Czechia, France and more

Ahead

  1. Nov 17, 2026Primary completion: phase 4 study in Hemophilia ASwedish Orphan Biovitrum · NCT06752850
  2. Jan 15, 2027Primary completion: phase 3 study in Hemophilia ASanofi · NCT04644575
  3. Mar 2027Primary completion: phase 3 study in Hemophilia ASwedish Orphan Biovitrum · NCT06716814
  4. Oct 25, 2027Primary completion: phase 4 study in Hemophilia ASanofi · NCT06941870

TargetBeta

F8 →read by rule
“A recombinant fusion protein comprising a single chain B-domain deleted (BDD) analog of human antihemophilic factor (coagulation factor VIII; FVIII) covalently ”NCIt, by rule
“Coagulation factor VIII exogenous protein”ChEMBL 37, by rule

Other programs on F8

ProgramCompanyFurthest phaseStudies
antihemophilic factor, human recombinantruleTakedaphase 416
omfiloctocog alfaruleSinocelltech Groupphase 46
lonoctocog alfaruleCSLphase 34

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06941870Hemophilia A · United States, Australia, Canada and more4RecruitingSanofiOct 25, 202735
NCT06940830Hemophilia A · Croatia, Czechia, France and more4Active, not recruitingSwedish Orphan BiovitrumDec 2028252
NCT06752850Hemophilia A · Italy, Norway, Spain and more4Active, not recruitingSwedish Orphan BiovitrumNov 17, 202637
NCT06716814Hemophilia A · Bulgaria, France, Greece and more3Active, not recruitingSwedish Orphan BiovitrumMar 202789
NCT06579144Hemophilia A · Bulgaria, Germany, Italy and more1CompletedSwedish Orphan BiovitrumMay 21, 202624
NCT05817812Hemophilia A · Austria, Croatia, Czechia and more3CompletedSwedish Orphan BiovitrumJun 2, 202693
NCT05042440Hemophilia A · Bulgaria1CompletedSanofiNov 24, 202113
NCT04770935von Willebrand Diseases · United States, France1CompletedSanofiDec 1, 20226
NCT04759131Hemophilia A · United States, Australia, Canada and more3CompletedSanofiJan 18, 202374
NCT04644575Hemophilia A · United States, Argentina, Australia and more3Active, not recruitingSanofiJan 15, 2027261
NCT04161495Hemophilia A · United States, Argentina, Australia and more3CompletedSanofiFeb 3, 2022159
NCT03205163Hemophilia A · United States, Japan2CompletedSanofiNov 12, 201816

How it is read

Names in the registry

  • “Efanesoctocog alfa”, 7 entries
  • “efanesoctocog alfa (BIVV001)”, 4 entries
  • “BIVV001 (Low Dose)”, 1 entry
  • “BIVV001 (High Dose)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.